Asset profile
Relatlimab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: adult and pediatric patients 12 years of age or older with unresectable or metastatic... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Relatlimab: this drug | Phase 3 | Monoclonal antibody | LAG-3 | ||
| HLX26 | Phase 2 | Monoclonal antibody | LAG-3 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
November 2026 (1)
Phase 2Melanoma, Brain MetastasesRecruiting
Est. primary completion 2026-11 · NCT06712927 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Gastroesophageal Cancer, Immune Checkpoint InhibitionActive not recruiting
Est. primary completion 2026-12 · NCT03610711 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the SkinRecruiting
Est. primary completion 2026-12 · NCT04204837 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06151236 · CT.gov ↗
What to watch
Phase 2Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases …Active not recruiting
Est. primary completion 2026-12-01 · NCT06237920 · CT.gov ↗
What to watch
Phase 2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Active not recruiting
Est. primary completion 2026-12-31 · NCT04953104 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Gastric Cancer, Esophageal Cancer, GastroEsophageal CancerActive not recruiting
Est. primary completion 2027-03 · NCT03044613 · CT.gov ↗
What to watch
June 2027 (2)
July 2027 (2)
September 2027 (1)
Phase 1Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8 …Recruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
Phase 2Cutaneous Melanoma, Mucosal MelanomaRecruiting
Est. primary completion 2028-03 · NCT06999980 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2028-05 · NCT06624475 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Melanoma (Skin)Recruiting
Est. primary completion 2028-07-31 · NCT05704647 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, MelanomaRecruiting
Est. primary completion 2028-11 · NCT06295159 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Renal Cell Carcinoma, Clear CellActive not recruiting
Est. primary completion 2028-12-15 · NCT06708949 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-01-04 · NCT06697197 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8Recruiting
Est. primary completion 2029-04-30 · NCT06029270 · CT.gov ↗
What to watch
May 2029 (2)
June 2029 (1)
Phase 2Newly Diagnosed GlioblastomaRecruiting
Est. primary completion 2029-06-01 · NCT06816927 · CT.gov ↗
What to watch
August 2029 (1)
2030 (6)
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
August 2030 (1)
September 2030 (1)
Phase 2/3Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma …Recruiting
Est. primary completion 2030-09-02 · NCT05987241 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 1/2Metastatic Melanoma, Liver MetastasesRecruiting
Est. primary completion 2030-12 · NCT07281924 · CT.gov ↗
What to watch
Phase 2LOCALLY ADVANCED CERVICAL CANCERSActive not recruiting
Est. primary completion 2030-12-31 · NCT06715241 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair DeficientNot yet recruiting
Est. primary completion 2033-03-01 · NCT07644312 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.